JP5520158B2 - 含窒素スピロ環化合物及びその医薬用途 - Google Patents

含窒素スピロ環化合物及びその医薬用途 Download PDF

Info

Publication number
JP5520158B2
JP5520158B2 JP2010171260A JP2010171260A JP5520158B2 JP 5520158 B2 JP5520158 B2 JP 5520158B2 JP 2010171260 A JP2010171260 A JP 2010171260A JP 2010171260 A JP2010171260 A JP 2010171260A JP 5520158 B2 JP5520158 B2 JP 5520158B2
Authority
JP
Japan
Prior art keywords
group
solvate
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010171260A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011046700A (ja
JP2011046700A5 (https=
Inventor
悟 野路
真 塩崎
智也 三浦
義典 原
山中　　浩
克也 前田
亜希美 堀
昌文 井上
康徳 長谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5520158(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to JP2010171260A priority Critical patent/JP5520158B2/ja
Publication of JP2011046700A publication Critical patent/JP2011046700A/ja
Publication of JP2011046700A5 publication Critical patent/JP2011046700A5/ja
Application granted granted Critical
Publication of JP5520158B2 publication Critical patent/JP5520158B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010171260A 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途 Active JP5520158B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010171260A JP5520158B2 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009179502 2009-07-31
JP2009179502 2009-07-31
JP2010171260A JP5520158B2 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014077850A Division JP2014141516A (ja) 2009-07-31 2014-04-04 含窒素スピロ環化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2011046700A JP2011046700A (ja) 2011-03-10
JP2011046700A5 JP2011046700A5 (https=) 2014-02-13
JP5520158B2 true JP5520158B2 (ja) 2014-06-11

Family

ID=43529436

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2010171260A Active JP5520158B2 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途
JP2014077850A Pending JP2014141516A (ja) 2009-07-31 2014-04-04 含窒素スピロ環化合物及びその医薬用途
JP2015224910A Ceased JP2016029104A (ja) 2009-07-31 2015-11-17 含窒素スピロ環化合物及びその医薬用途
JP2016214954A Ceased JP2017019877A (ja) 2009-07-31 2016-11-02 含窒素スピロ環化合物及びその医薬用途
JP2018028525A Ceased JP2018111701A (ja) 2009-07-31 2018-02-21 含窒素スピロ環化合物及びその医薬用途
JP2019219283A Withdrawn JP2020033384A (ja) 2009-07-31 2019-12-04 含窒素スピロ環化合物及びその医薬用途
JP2021144545A Withdrawn JP2021183653A (ja) 2009-07-31 2021-09-06 含窒素スピロ環化合物及びその医薬用途
JP2023128376A Withdrawn JP2023138641A (ja) 2009-07-31 2023-08-07 含窒素スピロ環化合物及びその医薬用途
JP2025077764A Withdrawn JP2025109780A (ja) 2009-07-31 2025-05-08 含窒素スピロ環化合物及びその医薬用途

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2014077850A Pending JP2014141516A (ja) 2009-07-31 2014-04-04 含窒素スピロ環化合物及びその医薬用途
JP2015224910A Ceased JP2016029104A (ja) 2009-07-31 2015-11-17 含窒素スピロ環化合物及びその医薬用途
JP2016214954A Ceased JP2017019877A (ja) 2009-07-31 2016-11-02 含窒素スピロ環化合物及びその医薬用途
JP2018028525A Ceased JP2018111701A (ja) 2009-07-31 2018-02-21 含窒素スピロ環化合物及びその医薬用途
JP2019219283A Withdrawn JP2020033384A (ja) 2009-07-31 2019-12-04 含窒素スピロ環化合物及びその医薬用途
JP2021144545A Withdrawn JP2021183653A (ja) 2009-07-31 2021-09-06 含窒素スピロ環化合物及びその医薬用途
JP2023128376A Withdrawn JP2023138641A (ja) 2009-07-31 2023-08-07 含窒素スピロ環化合物及びその医薬用途
JP2025077764A Withdrawn JP2025109780A (ja) 2009-07-31 2025-05-08 含窒素スピロ環化合物及びその医薬用途

Country Status (36)

Country Link
US (4) US8609647B2 (https=)
EP (3) EP3181570A1 (https=)
JP (9) JP5520158B2 (https=)
KR (1) KR101773208B1 (https=)
CN (1) CN102510865B (https=)
AR (1) AR077497A1 (https=)
AU (1) AU2010278066B2 (https=)
BR (1) BR112012002157B1 (https=)
CA (1) CA2767899C (https=)
CO (1) CO6491052A2 (https=)
CY (2) CY1118747T1 (https=)
DK (1) DK2460806T3 (https=)
ES (1) ES2616705T3 (https=)
FI (1) FIC20250012I1 (https=)
FR (1) FR25C1010I2 (https=)
HR (1) HRP20170447T1 (https=)
HU (2) HUE033070T2 (https=)
IL (1) IL217048A (https=)
LT (2) LT2460806T (https=)
ME (1) ME02667B (https=)
MX (1) MX2012001313A (https=)
MY (1) MY163495A (https=)
NL (1) NL301321I2 (https=)
NO (1) NO2025014I1 (https=)
NZ (1) NZ597994A (https=)
PE (1) PE20121276A1 (https=)
PL (1) PL2460806T3 (https=)
PT (1) PT2460806T (https=)
RS (1) RS55913B1 (https=)
RU (1) RU2630694C2 (https=)
SG (1) SG176918A1 (https=)
SI (1) SI2460806T1 (https=)
SM (1) SMT201700166T1 (https=)
TW (1) TWI466885B (https=)
WO (1) WO2011013785A1 (https=)
ZA (1) ZA201200689B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014141516A (ja) * 2009-07-31 2014-08-07 Japan Tobacco Inc 含窒素スピロ環化合物及びその医薬用途

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
KR101541086B1 (ko) * 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
PT2796460T (pt) 2011-12-21 2018-11-05 Shanghai hengrui pharmaceutical co ltd Derivado pirrole de anel heteroarilo de seis membros, método de preparação do mesmo e suas utilizações médicas
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
JP6427497B2 (ja) * 2013-10-21 2018-11-21 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
MX2016015613A (es) * 2014-05-28 2017-04-13 Astrazeneca Ab Procesos para la preparacion de azd5363 e intermedios novedosos utilizados en el mismo.
CA2991020A1 (en) * 2015-07-07 2017-01-12 Japan Tobacco Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
MY196541A (en) * 2015-09-24 2023-04-19 Leo Pharma As Treatment of Alopecia Areata
JP6767491B2 (ja) * 2015-09-25 2020-10-14 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｊａｋを阻害するための化合物及び方法
DK3405197T3 (da) 2016-01-21 2023-11-27 Leo Pharma As Topisk behandling af håndeksem
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
KR20190084299A (ko) * 2016-11-23 2019-07-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤로 6-원 헤테로방향족 고리 유도체의 제조 방법 및 그의 중간체
BR112019012688A2 (pt) * 2016-12-21 2019-11-19 Japan Tobacco Inc método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo
EP3559003B1 (en) * 2016-12-21 2022-08-24 Japan Tobacco Inc. Crystalline forms of a janus kinase inhibitor
TWI790218B (zh) * 2016-12-21 2023-01-21 日商日本煙草產業股份有限公司 7Ｈ－吡咯并[2,3－ｄ]嘧啶衍生物的製造方法及其共結晶
WO2018134352A1 (en) 2017-01-20 2018-07-26 Leo Pharma A/S Bicyclic amines as novel jak kinase inhibitors
RU2761626C2 (ru) * 2017-02-03 2021-12-13 Лео Фарма А/С ПРОИЗВОДНЫЕ 5-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-5-АЗАСПИРО[2.5]ОКТАН-8-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ НОВЫХ ИНГИБИТОРОВ JAK-КИНАЗЫ
US11149039B2 (en) * 2017-10-10 2021-10-19 Biogen Inc. Process for preparing spiro derivatives
PE20211455A1 (es) * 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
CN112384514A (zh) * 2018-07-06 2021-02-19 利奥制药有限公司 作为janus激酶抑制剂的新的氨基-咪唑并嘧啶衍生物及其药物用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
KR20220008893A (ko) 2019-05-15 2022-01-21 레오 파마 에이/에스 피부 홍반성 루푸스의 치료
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
WO2022117075A1 (zh) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途
WO2022143629A1 (zh) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 治疗与抗肿瘤剂相关的皮肤疾病或病症的试剂和方法
WO2023202989A1 (en) 2022-04-20 2023-10-26 Leo Pharma A/S Treatment of frontal fibrosing alopecia
AU2024229918A1 (en) 2023-02-28 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024194105A1 (en) 2023-03-17 2024-09-26 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2024225445A1 (en) 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4611524B2 (ja) 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
DE60037345T2 (de) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
DK1519939T5 (da) * 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
JPWO2005047286A1 (ja) * 2003-11-13 2007-05-31 小野薬品工業株式会社 スピロ複素環化合物
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20090111805A1 (en) 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
EP2354140A1 (en) * 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2007007919A2 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2008029237A2 (en) 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
CN101563323B (zh) 2006-12-22 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
CN101679440A (zh) * 2007-04-02 2010-03-24 帕劳制药股份有限公司 作为jak3抑制剂的吡咯并嘧啶衍生物
US20100298289A1 (en) * 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
US20110201599A1 (en) 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
JP2018028525A (ja) * 2016-08-15 2018-02-22 小野　信行 イオンレーザーと重水素を利用した核融合炉
JP6229778B2 (ja) * 2016-09-21 2017-11-15 サミー株式会社 遊技機

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014141516A (ja) * 2009-07-31 2014-08-07 Japan Tobacco Inc 含窒素スピロ環化合物及びその医薬用途
JP2017019877A (ja) * 2009-07-31 2017-01-26 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途
JP2018111701A (ja) * 2009-07-31 2018-07-19 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途
JP2020033384A (ja) * 2009-07-31 2020-03-05 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途
JP2021183653A (ja) * 2009-07-31 2021-12-02 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途
JP2023138641A (ja) * 2009-07-31 2023-10-02 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途
JP2025109780A (ja) * 2009-07-31 2025-07-25 日本たばこ産業株式会社 含窒素スピロ環化合物及びその医薬用途

Also Published As

Publication number Publication date
CA2767899A1 (en) 2011-02-03
RU2630694C2 (ru) 2017-09-12
SG176918A1 (en) 2012-01-30
SI2460806T1 (sl) 2017-04-26
CA2767899C (en) 2018-08-28
JP2011046700A (ja) 2011-03-10
AU2010278066A1 (en) 2012-03-01
EP3181570A1 (en) 2017-06-21
KR101773208B1 (ko) 2017-08-31
AU2010278066B2 (en) 2016-04-14
JP2023138641A (ja) 2023-10-02
FR25C1010I2 (fr) 2026-02-06
SMT201700166T1 (it) 2017-05-08
AR077497A1 (es) 2011-08-31
PT2460806T (pt) 2017-02-27
RS55913B1 (sr) 2017-09-29
JP2021183653A (ja) 2021-12-02
US20240150367A1 (en) 2024-05-09
HUE033070T2 (hu) 2017-11-28
CY1118747T1 (el) 2017-07-12
PL2460806T3 (pl) 2017-06-30
ME02667B (me) 2017-06-20
LTPA2025511I1 (https=) 2025-03-25
EP3858349A1 (en) 2021-08-04
JP2016029104A (ja) 2016-03-03
MX2012001313A (es) 2012-02-29
CN102510865A (zh) 2012-06-20
US20110136778A1 (en) 2011-06-09
BR112012002157B1 (pt) 2022-02-08
CY2025008I2 (el) 2026-02-25
NZ597994A (en) 2013-08-30
RU2012106344A (ru) 2013-08-27
TWI466885B (zh) 2015-01-01
EP2460806A1 (en) 2012-06-06
HRP20170447T1 (hr) 2017-05-19
HUS2500013I1 (hu) 2025-03-28
US20230023377A1 (en) 2023-01-26
FIC20250012I1 (fi) 2025-02-28
ES2616705T3 (es) 2017-06-14
BR112012002157A2 (pt) 2020-08-18
IL217048A0 (en) 2012-02-29
JP2014141516A (ja) 2014-08-07
LT2460806T (lt) 2017-02-10
US20140187534A1 (en) 2014-07-03
ZA201200689B (en) 2012-10-31
NO2025014I1 (no) 2025-03-04
JP2018111701A (ja) 2018-07-19
PE20121276A1 (es) 2012-09-27
JP2025109780A (ja) 2025-07-25
CO6491052A2 (es) 2012-07-31
DK2460806T3 (en) 2017-03-20
MY163495A (en) 2017-09-15
US8609647B2 (en) 2013-12-17
KR20120051649A (ko) 2012-05-22
EP2460806B1 (en) 2017-01-04
EP2460806A4 (en) 2012-12-26
WO2011013785A1 (ja) 2011-02-03
JP2017019877A (ja) 2017-01-26
NL301321I2 (nl) 2025-07-17
CN102510865B (zh) 2015-04-15
CY2025008I1 (el) 2026-02-25
IL217048A (en) 2014-12-31
TW201107325A (en) 2011-03-01
JP2020033384A (ja) 2020-03-05
FR25C1010I1 (fr) 2025-04-25

Similar Documents

Publication Publication Date Title
JP5520158B2 (ja) 含窒素スピロ環化合物及びその医薬用途
US10851116B2 (en) Bicyclic amines as novel JAK kinase inhibitors
JP7367004B2 (ja) 自己免疫疾患の処置のための新規のピラゾロビリジン化合物
HK1166499B (en) Nitrogen-containing spiro-ring compound and medicinal use of same
HK1166499A (en) Nitrogen-containing spiro-ring compound and medicinal use of same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131224

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131224

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140404

R150 Certificate of patent or registration of utility model

Ref document number: 5520158

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350